Survival among COPD patients using fluticasone/salmeterol in combination versus other inhaled steroids and bronchodilators alone

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 4, Issue 2, 2007, Pages 127-134

  Mapel, Douglas W ^a   Nelson, Leila S ^a   Lydick, Eva ^a   Soriano, Joan ^b   Yood, Marianne Ulcickas ^c   Davis, Kourtney J ^d  

^a LOVELACE CLINIC FOUNDATION   (United States)

^b Hospital Joan March   (Spain)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRONCHODILATING AGENT; CORTICOSTEROID; FLUTICASONE; SALMETEROL; STEROID; ANDROSTANE DERIVATIVE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; DRUG DERIVATIVE; FLUTICASONE SALMETEROL COMBINATION; FLUTICASONE-SALMETEROL COMBINATION; GLUCOCORTICOID; SALBUTAMOL; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENDER; HAZARD ASSESSMENT; HEALTH CARE DELIVERY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SURVIVAL; TIME SERIES ANALYSIS; TREATMENT DURATION; COHORT ANALYSIS; DRUG COMBINATION; INHALATIONAL DRUG ADMINISTRATION; MIDDLE AGED; MORTALITY; RETROSPECTIVE STUDY; SURVIVAL RATE;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-AGONISTS; ADULT; AGED; ALBUTEROL; ANDROSTADIENES; BRONCHODILATOR AGENTS; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 34547398090     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.1080/15412550701341111     Document Type: Article

References (32)

1. Calverley PMA. Inhaled corticosteroids are beneficial in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161:341-342.
2. Barnes PJ. Inhaled corticosteroids are not beneficial in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161:342-344.
3. The GOLD Scientific Committee. Global Strategy for the Diagnosis, Management, and Prevention of COPD, 2004 Update. Accessed at http://www.GOLDCOPD.com/-, December 1st, 2004.
4. Celli BR, MacNee W, Agusti A, et al. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir 2004; 23:932-946.
5. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320:1297-1303.
6. Mahler DA, Wire P, Horstman D, et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the discus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 166:1084-1091.
7. Calverley PM, Boonsawat W, Cseke Z, et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003; 22:912-919.
8. Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomized controlled trial. Lancet 2003; 361:449-456.
9. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003; 21:74-81.
10. Hanania NA, Darken P, Horstman D, et al. The efficacy and safety of fluticasone propionate (250 μg)/salmeterol (50 μg) combined in the discus inhaler for the treatment of COPD. Chest 2003; 124:834-843.
11. Sin DD, Tu JV. Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164:580-584.
12. Soriano JB, Vestbo J, Pride NB, Kiri V, Maden C, Maier WC. Survival in COPD patients after regular use of salmeterol and/or fluticasone propionate in general practice. Eur Resp J 2002; 20:1-7.
13. Sin DD, Man SF. Inhaled corticosteroids and survival in chronic obstructive pulmonary disease: does the dose matter? Eur Respir J 2003; 21:260-266.
14. Soriano JB, Kiri VA, Pride NB, Vestbo J. Inhaled corticosteroids with/without long-acting beta-agonists reduce the risk of rehospitalization and death in COPD patients. Am J Respir Med 01 Jan 2003; 2(1):67-74.
15. Mapel DW, Jurley JS, Roblin D, Roberts M, Davis KJ, Schreiner F, Frost FJ. Survivial of COPD patients using inhaled corticosteroids and long-acting beta agonists. Respiratory Medicine (In Press).
16. Suissa S. Effectiveness of inhaled corticosteroids in COPD: immortal time bias in observational studies. Am J Respir Crit Care Med 2003; 168:49-53.
17. Fan VS, Bryson CL, Curtis JR, et al. Inhaled corticosteroids in chronic obstructive pulmonary disease and risk of death and hospitalization. Am J Respir Crit Care Med 2003; 168:1488-1494.
18. Suissa S. Inhaled steroids and mortality in COPD: bias from unaccounted immortal time. Eur Respir J 2004; 23:391-395.
19. Fisher LD, Lin DY. Time-dependent covariates in the Cox proportional-hazards regression model. Annu Rev Public Health 1999; 20:145-157.
20. Sin DD, Man SF, Tu JV. Inhaled glucocorticoids in COPD: immortal time bias. Am J Respir Crit Care Med 2003; 168:126-127.
21. Kiri VA, Pride NB, Soriano JB, Vestbo J. Inhaled corticosteroids in chronic obstructive pulmonary disease: results from two observational designs free of immortal time bias. Am J Respir Crit Care Med 2005; 172(4):460-464.
22. Kiri VA, Bettoncelli G, Testi R, Viegi G. Inhaled corticosteroids are more effective in COPD patients when used with LABA than with SABA. Respir Med 2005; 99(9):1115-1124.
23. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992; 45:613-619.
24. Collett, D. Modelling Survival Data in Medical Research, Second Edition. Boca Raton, FL, Chapman & Hall/CRC, 2003.
25. Ghali WA, Quan H, Rollin B et al. Comparison of 2 methods for adjusted survival curves from proportional hazards models. JAMA 2001; 286(12):1494-1497.
26. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998; 17:2265-2281.
27. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997; 127:757-763.
28. Joffe MM, Rosenbaum PR. Invited commentary: propensity scores. Am J Epidemiol 1999; 150:327-333.
29. Drake C, Fisher L. Prognostic models and the propensity score. Int J Epidemiol 1995; 24:183-187.
30. Breslow NE. Statistics in Epidemiology: The case-control study. J Ame Stat Asso 1996; 91:14-28.
31. Calverly PMA, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356(8): 775-789.
32. Sin DD, Wu L, Anderson JA, Anthonisen NR, Buist AS, Burge PS, Calverley PM, Connett JE, Lindmark B, Pauwels RA, Postma DS, Soriano JB, Szafranski W, Vestbo J. Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax 2005; 60(12):992-997.